DGAP-Adhoc: LANXESS signs contract to acquire Chemtura


LANXESS Aktiengesellschaft  / Key word(s): Takeover

26.09.2016 00:24

Disclosure of an inside information according to Article 17 MAR,
transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Cologne - Specialty chemicals company LANXESS has signed a contract to take
over the US-based specialty chemicals company Chemtura Corporation.
Chemtura is one of the major global providers of high-quality flame
retardant- and lubricant additives. LANXESS is offering all cash
consideration of USD 33.50 per share.

For the transaction with an enterprise value of  around EUR 2.4 billion
LANXESS has secured bridge financing. The bridge financing will quickly be
refinanced via senior bonds and a hybrid bond. Furthermore, LANXESS will
use existing liquidity for financing.
Closing is subject to approval by Chemtura shareholders, any required
regulatory approvals and certain other customary closing conditions.
Closing of the transaction is anticipated mid-2017.

Chemtura employs worldwide approximately 2,500 employees and has 20 sites
in 11 countries. The company's headquarters are in Philadelphia,
Pennsylvania. The stock market listed company reported sales of around EUR
1.5 billion in the last four quarters and EBITDA pre exceptionals of
approximately EUR 245 million. Around 45 percent of its turnover are
generated in North America. In addition to additives, the portfolio also
comprised urethanes and organometallics.

A combination of both companies would materially expand LANXESS' business
activities in additives for lubricants and flame retardants.

Against the backdrop of the acquisition, the announced share buy-back of
around EUR 200 million will not be pursued further.


Cologne, September  25, 2016 

Forward-Looking Statements 
This company release contains certain forward-looking statements, including
assumptions, opinions and
views of the company or cited from third party sources. Various known and
unknown risks, uncertainties
and other factors could cause the actual results, financial position,
development or performance of
LANXESS AG to differ materially from the estimations expressed or implied
herein. LANXESS AG does
not guarantee that the assumptions underlying such forward-looking
statements are free from errors nor
does it accept any responsibility for the future accuracy of the opinions
expressed in this presentation or
the actual occurrence of the forecast developments. No representation or
warranty (expressed or
implied) is made as to, and no reliance should be placed on, any
information, estimates, targets and
opinions, contained herein, and no liability whatsoever is accepted as to
any errors, omissions or
misstatements contained herein, and accordingly, no representative of
LANXESS AG or any of its
affiliated companies or any of such person's officers, directors or
employees accept any liability
whatsoever arising directly or indirectly from the use of this document.  

Important Additional Information 

This company release relates to the proposed acquisition of Chemtura Corp.
by LANXESS AG.  The information included herein is being provided for
informational purposes only and does not constitute an offer to sell, or a
solicitation of an offer to purchase, any securities, nor a solicitation of
any vote or approval. No public market exists for the securities of LANXESS
AG in the United States.
The proposed acquisition will be submitted to the stockholders of Chemtura
Corp. for their consideration. In connection therewith, Chemtura Corp.
intends to file a proxy
statement with the U.S. Securities and Exchange Commission ("SEC") and mail
such proxy statement to its stockholders of record. BEFORE MAKING ANY
VOTING OR ANY INVESTMENT DECISION,
INVESTORS AND STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT

REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS FILED 
OR TO BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY
BECOME
AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE 
PROPOSED TRANSACTION. Investors and stockholders will be able to obtain
free copies of the proxy
statement, any amendments or supplements thereto and other documents
containing important
information about Chemtura Corp., once such documents are filed with the
SEC, through the website
maintained by the SEC at www.sec.gov. Copies of the documents filed with
the SEC by Chemtura
Corp. will be available free of charge on Chemtura Corp.'s website at
http://investor.chemtura.com
under the heading "Financials & Filings". Stockholders of Chemtura Corp.
may also obtain a free copy
of the definitive proxy statement by contacting Chemtura Corp.'s Investor
Relations Department at
+1 (203) 573-2153.


26.09.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      LANXESS Aktiengesellschaft
              Kennedyplatz 1
              50569 Köln
              Germany
Phone:        +49 (0)221 8885-0
Fax:          +49 (0)221 8885-4944
E-mail:       ir@lanxess.com
Internet:     www.lanxess.com
ISIN:         DE0005470405
WKN:          547040
Indices:      MDAX
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated
              Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
              Munich, Stuttgart, Tradegate Exchange
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------